Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Gestational diabetes mellitus - Neonatal and maternal outcomes in women treated with insulin or diet: A propensity matched analysis","authors":"Sunil S. Gupta ,&nbsp;Shlok S. Gupta ,&nbsp;Rajeev Chawla ,&nbsp;Kavita S. Gupta ,&nbsp;Parvinder R. Bamrah ,&nbsp;Rutul A. Gokalani","doi":"10.1016/j.dsx.2024.103145","DOIUrl":"10.1016/j.dsx.2024.103145","url":null,"abstract":"<div><h3>Aims</h3><div>Pregnant women worldwide face the risk of developing gestational diabetes mellitus (GDM), if left untreated, can cause complications. The study explores factors influencing the choice between diet control and insulin therapy for pregnant women with GDM. It aims to understand how these choices impact maternal and neonatal outcomes.</div></div><div><h3>Methods</h3><div>In this quasi-experimental study, clinicians determined treatment (diet control or insulin) for 1030 individuals with GDM at a private practice from 2010 to 2020 based on baseline characteristics. Propensity scores (PS), reflecting the probability of treatment allocation, were derived through multiple logistic regression.</div></div><div><h3>Results</h3><div>After PS matching, 386 individuals were paired from two study groups. The insulin-treated group exhibited a 4.43 times higher risk of neonatal hypoglycemia than the diet group. Insulin-treated individuals, stratified by PS, revealed that the high-risk quartile had significantly higher mean insulin requirements and a doubled dose at full term compared to the lower-risk quartiles. The mean insulin dose did not significantly differ in the first three quartiles, but the last quartile showed a significant increase (p = 0.008), particularly for individuals with PS exceeding 0.70, indicating a higher insulin dose requirement for effective glucose control.</div></div><div><h3>Conclusion</h3><div>This study reveals that individuals with a bad obstetrics history, a family history of diabetes, obesity, and elevated baseline glycemic parameters necessitate higher insulin doses. This insight improves clinicians' decision-making in diagnosis and treatment planning, enhancing the precision of medical practices.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103145"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of and barriers to diabetes care among patients with serious mental illness: A scoping review with recommendations","authors":"A.S. Prathiksha ,&nbsp;Pawar Mansi Shantaram ,&nbsp;Muhammed Rashid ,&nbsp;Pooja Gopal Poojari ,&nbsp;Sreedharan Nair ,&nbsp;Leelavathi D. Acharya ,&nbsp;Girish Thunga","doi":"10.1016/j.dsx.2024.103139","DOIUrl":"10.1016/j.dsx.2024.103139","url":null,"abstract":"<div><h3>Aim</h3><div>We performed a scoping review to identify the diabetes care determinants and barriers in patients with serious mental illness (SMI), in view of limited evidence and clarity.</div></div><div><h3>Methods</h3><div>We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Guidelines. PubMed, EMBASE, and Scopus were searched from inception to September 2023 to identify eligible studies. Observational studies that reported the determinants of and barriers to diabetes care among SMI patients were considered. A narrative synthesis of review results was performed to gather evidence. Recommendations were framed in the context of this evidence.</div></div><div><h3>Results</h3><div>Of the 8727 non-duplicate records, only 10 studies that met the inclusion criteria were considered for this review. Of these, four were cohort, two were case-control, and four were cross-sectional in design. All 10 studies were observed to have robust methodologies. Diabetes measures examined in these studies included not only the Healthcare Effectiveness Data and Information Set (HEDIS) measures (HbA1c, retinopathy, nephropathy, and blood pressure), but also lipid, foot, and BMI. Factors contributing to inadequate diabetes care can be attributed to the healthcare system, healthcare providers, and at the patient-level.</div></div><div><h3>Conclusion</h3><div>Currently, there is lack of evidence on determinants of quality diabetes care among SMI patients. Further, adequately powered long term follow-up studies are needed to understand the impact of diabetes care on their clinical outcomes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103139"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142532067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA-34a and promoter methylation contribute to peroxisome proliferator-activated receptor gamma gene expression in patients with type 2 diabetes","authors":"Mona Moghadasi ,&nbsp;Mozhgan Taherimoghaddam ,&nbsp;Esmaeel Babaeenezhad ,&nbsp;Mehdi Birjandi ,&nbsp;Mozhgan Kaviani ,&nbsp;Mostafa Moradi Sarabi","doi":"10.1016/j.dsx.2024.103156","DOIUrl":"10.1016/j.dsx.2024.103156","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to investigate the roles of DNA methylation and miR-34a in the regulation of peroxisome proliferator-activated receptor gamma (<em>PPARγ</em>) in patients with type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>We investigated the methylation status of four regions of the <em>PPARγ</em> promoter and <em>PPARγ</em> expression in a panel of 84 T2D patients using methylation-specific PCR (MSP) and RT-qPCR, respectively. Moreover, we quantified DNA methyltransferases (<em>DNMTs</em>) expression and global DNA methylation levels by RT-qPCR and ELISA, respectively. We measured the expression levels of miR-34a and protein expression of PPARγ by stem-loop RT-qPCR and ELISA, respectively.</div></div><div><h3>Results</h3><div>We found significant DNA hypermethylation in the R2 and R3 regions of the <em>PPARγ</em> promoter in people with diabetes. Functionally, this was associated with a significant reduction in <em>PPARγ</em> expression. In addition, we observed a significant increase in 5-methylcytosine levels in people with diabetes. A marked increase in circulating miR-34a in the early stages of T2D (up to 10 years) and a significant decrease in circulating miR-34a with increasing diabetes duration from 10 years after the onset of diabetes. Interestingly, upregulation of DNA methyltransferases 1 (<em>DNMT1</em>), <em>DNMT3A</em>, and <em>DNMT3B</em> was observed in people with diabetes, and the average expression of <em>DNMTs</em> was negatively correlated with circulating miR-34a levels. In contrast, the serum protein level of PPARγ, a direct target of miR-34a, increased considerably with diabetes duration and showed a negative correlation with circulating miR-34a, cholesterol, triglyceride, and low-density lipoprotein.</div></div><div><h3>Conclusion</h3><div><em>PPARγ</em> promoter hypermethylation and miR-34a upregulation are associated with T2D pathogenesis through <em>PPARγ</em> dysregulation.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103156"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness of delivery modalities of non-pharmacological diabetes prevention programs: A systematic review and component network meta-analysis","authors":"Ellesha A. Smith ,&nbsp;Stephanie J. Hubbard ,&nbsp;Suzanne C. Freeman ,&nbsp;Daniel S. March ,&nbsp;Molly Wells ,&nbsp;Elnaz Saeedi ,&nbsp;Louise Haddon ,&nbsp;Kamlesh Khunti ,&nbsp;Laura J. Gray","doi":"10.1016/j.dsx.2024.103136","DOIUrl":"10.1016/j.dsx.2024.103136","url":null,"abstract":"<div><h3>Background and aims</h3><div>Type 2 diabetes prevention programs are effective but costly and intensive, making translation into routine primary care and community settings challenging. Identifying drivers of intervention effectiveness can inform pragmatic future implementation whilst maintaining effectiveness. Translational studies have demonstrated that delivery modalities impact their effectiveness. This systematic review and component network meta-analysis assessed which delivery modality components of non-pharmacological diabetes prevention programs are associated with reductions in type 2 diabetes incidence for individuals at high risk of type 2 diabetes (or pre-diabetes).</div></div><div><h3>Methods</h3><div>We searched MEDLINE, The Cochrane Library, Opengrey and <span><span>clinicaltrials.gov</span><svg><path></path></svg></span> from inception to November 17, 2022 for translational studies comparing lifestyle interventions with a minimum 12-month follow-up. Two investigators extracted the data. Random effects network meta-analyses and component network meta-analyses estimated the intervention effects.</div></div><div><h3>Results</h3><div>We identified 50 eligible studies involving 29,286 participants including thirty-six (72.0 %) randomized controlled trials, 10 (20.0 %) cluster randomized controlled trials, and four (8.0 %) observational studies. Component network meta-analyses found in-person (individually) delivery was associated with greater reduction in incidence of type 2 diabetes (hazard ratio: 0.66, 95 % credible interval: 0.41, 0.96) and in-person (group-based) delivery was associated with greater reductions in weight (mean difference: −1.53 kg, 95 % credible interval: −2.18, −0.85) and HbA1c (mean difference: −0.74 mmol/mol, 95 % credible interval: −1.28, −0.17), relative to usual care.</div></div><div><h3>Conclusions</h3><div>This analysis suggests in-person delivery modalities are most effective for diabetes prevention. Future research should focus on improving the effectiveness of digital programs and ensuring preferential delivery for target populations to reduce health inequalities.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103136"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142445139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The triglyceride-glucose index, blood glucose levels, and metabolic syndrome are associated with all-cause mortality in obesity","authors":"Antonio E. Pontiroli ,&nbsp;Lucia Centofanti ,&nbsp;Ahmed S. Zakaria ,&nbsp;Simona Cerutti ,&nbsp;Michele Dei Cas ,&nbsp;Rita Paroni ,&nbsp;Lucia La Sala ,&nbsp;Elena Tagliabue ,&nbsp;Silvia Magnani ,&nbsp;Franco Folli","doi":"10.1016/j.dsx.2024.103146","DOIUrl":"10.1016/j.dsx.2024.103146","url":null,"abstract":"<div><h3>Background</h3><div>The Triglyceride-Glucose Index (TYG) has been proposed as a prognostic index for mortality in the general population, in T2DM, and in patients with cardiovascular diseases. However, data on the respective predictive roles of TYG, glucose tolerance (GT), and metabolic syndrome (MS) for mortality in obesity are lacking.</div></div><div><h3>Methods</h3><div>We analyzed 1359 obese patients (371 men and 988 women), aged 44.1 ± 12.64 years, followed for 14.3 ± 4.44 years. They were subdivided according to glucose tolerance, in normal glucose tolerance (NGT), impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM). We analyzed the risk of death associated with blood glucose (BG) quartiles, TYG quartiles and MS quartiles. Cox proportional-hazard models were used to evaluate the risk of death associated with independent variables that were highly statistically significant at univariate analysis.</div></div><div><h3>Results</h3><div>Different degrees of glucose tolerance were associated with a progressive deterioration of clinical outcomes, and increased all-cause mortality (6.3 %, 10.1 %, and 20.4 %, respectively). In all groups, age and male sex were associated with increased mortality. Higher TYG or TYG quartiles, BG or BG quartiles, and MS or MS quartiles were all associated with increased all-cause mortality in the whole cohort.</div></div><div><h3>Conclusion</h3><div>TYG, blood glucose and MS are risk factors for mortality in obesity, with a progressively stronger value in IFG and T2DM as compared to NGT.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103146"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dipeptidyl peptidase-4 inhibitors may lower body temperature: A case-control study","authors":"Shuichi Okada ,&nbsp;Kazuya Okada ,&nbsp;Junichi Okada ,&nbsp;Koji Kikkawa ,&nbsp;Eijiro Yamada ,&nbsp;Tsugumichi Saito ,&nbsp;Tetsuro Andou ,&nbsp;Kihachi Ohshima ,&nbsp;Yawara Niijima","doi":"10.1016/j.dsx.2024.103142","DOIUrl":"10.1016/j.dsx.2024.103142","url":null,"abstract":"<div><h3>Aims</h3><div>Dipeptidyl peptidase-4 inhibitors (DPP4i) enhance GABAergic transmission via the glucagon-like peptide-1 (GLP-1)/GLP-1 receptor pathway. Oral γ-aminobutyric acid (GABA) administration reduces body temperature in humans; thus, DPP4i may reduce body temperature in humans. Therefore, this study aimed to determine the effects of DPP4i administration on the body temperature of patients with type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>This study included 128 outpatients with T2D who visited the hospital monthly from May to July 2022. The DPP4i group included 64 patients treated with DPP4i while the non-DPP4i group included 64 patients not treated with DPP4i. Body temperature was measured at the axilla point upon entry to the hospital and was compared between the two groups.</div></div><div><h3>Results</h3><div>The means of age, body mass index, T2D duration, systolic blood pressure, diastolic blood pressure, serum creatinine level, casual triglyceride level, high-density lipoprotein cholesterol level, low-density lipoprotein cholesterol level, casual plasma glucose level, and glycated hemoglobin level were not significantly different between the two groups. The mean body temperatures (°C) were 36.1 ± 0.2 and 36.4 ± 0.17 in the DPP4i and non-DPP4i groups, respectively (<em>p</em> = 1.123 E−05).</div></div><div><h3>Conclusions</h3><div>DPP4i reduced the body temperature of patients with T2D.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103142"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum lipid peroxidation potential as a biomarker for risk-stratification of coronary artery disease in patients with type 2 diabetes mellitus","authors":"Kavya Sugur ,&nbsp;Swetha N. Kempegowda ,&nbsp;Sunil K. Shambu ,&nbsp;Manjappa Mahadevappa ,&nbsp;Vinay K. Kengegowda ,&nbsp;Jadeppa Gowda ,&nbsp;Rajesh K. Thimmulappa","doi":"10.1016/j.dsx.2024.103143","DOIUrl":"10.1016/j.dsx.2024.103143","url":null,"abstract":"<div><h3>Aim</h3><div>We examined the serum lipid peroxidation potential as an estimate of systemic oxidative stress levels in people with type 2 diabetes (T2D) for coronary artery disease (CAD) risk stratification.</div></div><div><h3>Methods</h3><div>We prospectively recruited patients and categorized them into four subgroups based on diabetes and severity of CAD [Gensini score &lt;20, non-significant CAD; Gensini score &gt;20, significant CAD]: non-diabetics with non-significant CAD, diabetics with non-significant CAD, non-diabetics with significant CAD and diabetics with significant CAD. Lipid profile, HbA1c, fasting blood glucose, and oxidized LDL were assessed. A newly developed assay estimated serum lipid peroxidation potential.</div></div><div><h3>Results</h3><div>Circulatory oxidized LDL levels were significantly higher in patients with severe CAD compared to non-diabetics with non-significant CAD, however no significant differences were observed across the four subgroups. Diabetics with non-significant CAD demonstrated significantly elevated serum lipid peroxidation potential compared to non-diabetics with non-significant CAD. Intriguingly, serum lipid peroxidation potential was markedly elevated in diabetics with non-significant CAD compared to both diabetics and non-diabetics with significant CAD. Poor glycemic control and reduced blood total antioxidant capacity were the primary factors contributing to increased serum lipid peroxidation potential in diabetics with non-significant CAD group.</div></div><div><h3>Conclusions</h3><div>We found that people with T2D who are associated with non-significant CAD are more vulnerable to oxidative stress than those with significant CAD. The study demonstrates the application of 'serum lipid peroxidation potential' assay for risk-stratification of CAD in people with T2D.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103143"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142555063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the Current Issue","authors":"Ningjian Wang ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2024.103158","DOIUrl":"10.1016/j.dsx.2024.103158","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103158"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical effectiveness and safety of preoperative oral carbohydrate loading in patients with diabetes: A systematic review","authors":"Chunxiu Zhao ,&nbsp;Jinghong Shi ,&nbsp;Na Zhu ,&nbsp;Pingliang Yang ,&nbsp;Bingbing Xiang ,&nbsp;Yunke Dai ,&nbsp;Shun Wang","doi":"10.1016/j.dsx.2024.103140","DOIUrl":"10.1016/j.dsx.2024.103140","url":null,"abstract":"<div><h3>Background</h3><div>The effectiveness and safety of preoperative oral carbohydrate (POC) for people with diabetes remain controversial.</div></div><div><h3>Methods</h3><div>We systematically reviewed studies comparing POC to fasting or placebo in elective surgery for diabetic adults, focusing on gastric volume, postoperative complications, hospital stay, and glycemic control.</div></div><div><h3>Results</h3><div>Fourteen studies (n = 1870 patients) were included. POC did not significantly increase gastric volume or aspiration risk in well-controlled type 2 diabetes. Effects on perioperative glucose control varied. POC improved patient comfort and reduced preoperative hypoglycemia in gestational diabetes. Limited evidence suggested potential benefits in cardiac surgery patients.</div></div><div><h3>Conclusion</h3><div>POC is safe for well-controlled type 2 diabetics, enhancing comfort and reducing preoperative hypoglycemia without increasing aspiration risk. However, its effects on glucose control and postoperative outcomes vary. Personalized approaches are crucial, particularly for poorly controlled diabetes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103140"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ٍEffects of Sumac Consumption on Blood Pressure, Glycemic Indices, and Body Composition in Adults: A GRADE-assessed Systematic Review and Dose-response Meta-analysis","authors":"Shaghayegh Taheri ,&nbsp;Zahra Sohrabi ,&nbsp;Hossein Bahari ,&nbsp;Seyedeh Nooshan Mirmohammadali ,&nbsp;Mohammad Hashem Hashempur ,&nbsp;Haniyeh Golafrouz ,&nbsp;Neda Haghighat ,&nbsp;Omid Asbaghi","doi":"10.1016/j.dsx.2024.103122","DOIUrl":"10.1016/j.dsx.2024.103122","url":null,"abstract":"<div><h3>Background</h3><div>Owing to the rich phytochemical content of <em>Rhus coriaria</em> L. (Anacardiaceae), known as Sumac, it may affect blood pressure, glycemic, and anthropometric indices. We, therefore, aimed to examine evidence on effect of Sumac on these factors by conducting a meta-analysis of RCTs.</div></div><div><h3>Methods</h3><div>A systematic literature search up to January 2024 was completed in PubMed/Medline, Scopus, and Web of Science. Heterogeneity tests of the selected trials were performed using the I² statistic. Random effects models were assessed based on the heterogeneity tests, and pooled data were determined as weighted mean differences (WMD) with a 95 % confidence interval (CI).</div></div><div><h3>Results</h3><div>Fifteen RCTs were included in this meta-analysis. Our findings showed that Sumac consumption significantly reduced diastolic blood pressure (DBP) (WMD = −2.88 mmHg; 95 %CI, −4.22 to −1.54; P = 0.001), fasting blood glucose (FBG) (WMD = −5.15 mg/dL; 95 %CI, −8.73 to −1.57; P = 0.005), insulin (WMD = −1.95 uIU/ml; 95 %CI, 3.11 to −0.79; P = 0.001), Hemoglobin A1c (WMD = −0.48 %; 95 %CI -0.84 to −0.12; P = 0.001), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (WMD = −0.71; 95 %CI, −1.14 to −0.27; P = 0.001), and waist to hip ratio (WHR) (WMD = −0.01; 95 %CI, −0.02 to −0.00; P = 0.017). Sumac consumption had no significant effects on weight, body mass index, and waist circumference.</div></div><div><h3>Conclusion</h3><div>We found that Sumac consumption could improve DBP, glycemic indices, and WHR. Also, supplementation of this herb in higher doses or longer durations had more promising effects on FBG, HOMA-IR, and WHR.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103122"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}